Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429344 | 0.81 | EPHX2 (0.66) | EPHX2HDAC8MAPK1MTNR1AMTNR1B | |
| SCHEMBL30767948 | 0.81 | EPHX2 (0.73) | EPHX2HDAC8MAPK1 | |
| SCHEMBL649195 | 0.77 | HDAC8 (0.60) | EPHX2HDAC8MAPK1 | |
| SCHEMBL7239168 | 0.77 | HDAC8 (0.52) | EPHX2HDAC8MAPK1HDAC1HDAC6 | |
| SCHEMBL5314136 | 0.77 | PYGL (0.45) | — | |
| SCHEMBL29012624 | 0.76 | GABRP (0.38) | MTNR1AMTNR1B | |
| SCHEMBL7246422 | 0.73 | HDAC8 (0.46) | EPHX2HDAC8MAPK1 | |
| SCHEMBL25331100 | 0.72 | HDAC8 (0.36) | EPHX2HDAC8MAPK1HDAC1HDAC6 | |
| SCHEMBL429139 | 0.71 | HDAC8 (0.51) | EPHX2HDAC8MAPK1 | |
| SCHEMBL31659540 | 0.70 | CHRNB2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | EPHX2 2674/4885HDAC8 1805/4885MAPK1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.